+1 (704) 266-3234

Ovarian Cancer Pipeline Review H1 2017

Published on: Jun 2017 | From USD $2500 | Published By: GMD | Number Of Pages: 2027

Ovarian Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 15, 135, 128, 7, 208, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 14, 43 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
Introduction 12
Ovarian Cancer - Overview 13
Ovarian Cancer - Therapeutics Development 14
Ovarian Cancer - Therapeutics Assessment 73
Ovarian Cancer - Companies Involved in Therapeutics Development 105
Ovarian Cancer - Drug Profiles 254
Ovarian Cancer - Dormant Projects 1928
Ovarian Cancer - Discontinued Products 1947
Ovarian Cancer - Product Development Milestones 1951
Appendix 1968

List of Tables
Number of Products under Development for Ovarian Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Products under Development by Companies, H1 2017 (Contd..19), H1 2017
Products under Development by Companies, H1 2017 (Contd..20), H1 2017
Products under Development by Companies, H1 2017 (Contd..21), H1 2017
Products under Development by Companies, H1 2017 (Contd..22), H1 2017
Products under Development by Companies, H1 2017 (Contd..23), H1 2017
Products under Development by Companies, H1 2017 (Contd..24), H1 2017
Products under Development by Companies, H1 2017 (Contd..25), H1 2017
Products under Development by Companies, H1 2017 (Contd..26), H1 2017
Products under Development by Companies, H1 2017 (Contd..27), H1 2017
Products under Development by Companies, H1 2017 (Contd..28), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by 4SC AG, H1 2017
Ovarian Cancer - Pipeline by AB Science SA, H1 2017
Ovarian Cancer - Pipeline by AbbVie Inc, H1 2017
Ovarian Cancer - Pipeline by AbGenomics International Inc, H1 2017
Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2017
Ovarian Cancer - Pipeline by Aduro BioTech Inc, H1 2017
Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H1 2017
Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017
Ovarian Cancer - Pipeline by Advantagene Inc, H1 2017
Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H1 2017
Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Alkermes Plc, H1 2017
Ovarian Cancer - Pipeline by Almac Discovery Ltd, H1 2017
Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H1 2017
Ovarian Cancer - Pipeline by Alteogen Inc, H1 2017
Ovarian Cancer - Pipeline by Altor BioScience Corp, H1 2017
Ovarian Cancer - Pipeline by Ambrx Inc, H1 2017
Ovarian Cancer - Pipeline by Amgen Inc, H1 2017
Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H1 2017
Ovarian Cancer - Pipeline by ANP Technologies Inc, H1 2017
Ovarian Cancer - Pipeline by AntiCancer Inc, H1 2017
Ovarian Cancer - Pipeline by Antigen Express Inc, H1 2017
Ovarian Cancer - Pipeline by Antoxis Ltd, H1 2017
Ovarian Cancer - Pipeline by Aphios Corp, H1 2017
Ovarian Cancer - Pipeline by Aposense Ltd, H1 2017
Ovarian Cancer - Pipeline by Aprea AB, H1 2017
Ovarian Cancer - Pipeline by arGEN-X BV, H1 2017
Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Arno Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by ArQule Inc, H1 2017
Ovarian Cancer - Pipeline by Array BioPharma Inc, H1 2017
Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
Ovarian Cancer - Pipeline by Arvinas Inc, H1 2017
Ovarian Cancer - Pipeline by Astellas Pharma Inc, H1 2017
Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by AstraZeneca Plc, H1 2017
Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Athenex Inc, H1 2017
Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Avipep Pty Ltd, H1 2017
Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H1 2017
Ovarian Cancer - Pipeline by Bayer AG, H1 2017
Ovarian Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H1 2017
Ovarian Cancer - Pipeline by BioCancell Ltd, H1 2017
Ovarian Cancer - Pipeline by BioMoti Ltd, H1 2017
Ovarian Cancer - Pipeline by Bionomics Ltd, H1 2017
Ovarian Cancer - Pipeline by BioNTech AG, H1 2017
Ovarian Cancer - Pipeline by Biotest AG, H1 2017
Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Ovarian Cancer - Pipeline by Boston Biomedical Inc, H1 2017
Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Cavion LLC, H1 2017
Ovarian Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Celgene Corp, H1 2017
Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Cellectar Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by Celleron Therapeutics Ltd, H1 2017
Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H1 2017
Ovarian Cancer - Pipeline by Celon Pharma SA, H1 2017
Ovarian Cancer - Pipeline by Celprogen Inc, H1 2017
Ovarian Cancer - Pipeline by Celsion Corp, H1 2017
Ovarian Cancer - Pipeline by Celyad SA, H1 2017
Ovarian Cancer - Pipeline by Ceronco Biosciences, H1 2017
Ovarian Cancer - Pipeline by CerRx Inc, H1 2017
Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2017
Ovarian Cancer - Pipeline by Cielo Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Clovis Oncology Inc, H1 2017
Ovarian Cancer - Pipeline by CohBar Inc, H1 2017
Ovarian Cancer - Pipeline by Coherus BioSciences Inc, H1 2017
Ovarian Cancer - Pipeline by Commence Bio Inc, H1 2017
Ovarian Cancer - Pipeline by Compliment Corp, H1 2017
Ovarian Cancer - Pipeline by Corcept Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
Ovarian Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by CytRx Corp, H1 2017
Ovarian Cancer - Pipeline by CZ BioMed Corp, H1 2017
Ovarian Cancer - Pipeline by DAE HWA Pharmaceutical Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
Ovarian Cancer - Pipeline by DEKK-TEC Inc, H1 2017
Ovarian Cancer - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
Ovarian Cancer - Pipeline by Ecrins Therapeutics SAS, H1 2017
Ovarian Cancer - Pipeline by Eisai Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2017
Ovarian Cancer - Pipeline by Endocyte Inc, H1 2017
Ovarian Cancer - Pipeline by EntreChem SL, H1 2017
Ovarian Cancer - Pipeline by Epigen Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by EpiThany Inc, H1 2017
Ovarian Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Exelixis Inc, H1 2017
Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Ovarian Cancer - Pipeline by Faron Pharmaceuticals Oy, H1 2017
Ovarian Cancer - Pipeline by Fate Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Forty Seven Inc, H1 2017
Ovarian Cancer - Pipeline by Fujifilm Corp, H1 2017
Ovarian Cancer - Pipeline by Galena Biopharma Inc, H1 2017
Ovarian Cancer - Pipeline by GamaMabs Pharma SA, H1 2017
Ovarian Cancer - Pipeline by Gene Techno Science Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Genelux Corp, H1 2017
Ovarian Cancer - Pipeline by Genentech Inc, H1 2017
Ovarian Cancer - Pipeline by Genisphere LLC, H1 2017
Ovarian Cancer - Pipeline by Genmab A/S, H1 2017
Ovarian Cancer - Pipeline by Genor BioPharma Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Gilead Sciences Inc, H1 2017
Ovarian Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
Ovarian Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
Ovarian Cancer - Pipeline by GlycoNex Inc, H1 2017
Ovarian Cancer - Pipeline by Glycotope GmbH, H1 2017
Ovarian Cancer - Pipeline by GP Pharm SA, H1 2017
Ovarian Cancer - Pipeline by Gradalis Inc, H1 2017
Ovarian Cancer - Pipeline by GW Pharmaceuticals Plc, H1 2017
Ovarian Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Hemispherx Biopharma Inc, H1 2017
Ovarian Cancer - Pipeline by Horizon Pharma Plc, H1 2017
Ovarian Cancer - Pipeline by Ideaya Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by Ignyta Inc, H1 2017
Ovarian Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
Ovarian Cancer - Pipeline by IMMD Inc, H1 2017
Ovarian Cancer - Pipeline by Immune Design Corp, H1 2017
Ovarian Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Immune Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Immunocore Ltd, H1 2017
Ovarian Cancer - Pipeline by ImmunoGen Inc, H1 2017
Ovarian Cancer - Pipeline by Immunomedics Inc, H1 2017
Ovarian Cancer - Pipeline by Immunovaccine Inc, H1 2017
Ovarian Cancer - Pipeline by IMPACT Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Incyte Corp, H1 2017
Ovarian Cancer - Pipeline by Innate Immunotherapeutics Ltd, H1 2017
Ovarian Cancer - Pipeline by Innate Pharma SA, H1 2017
Ovarian Cancer - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Insys Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Inventiva, H1 2017
Ovarian Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Johnson & Johnson, H1 2017
Ovarian Cancer - Pipeline by Juno Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Komipharm International Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Ovarian Cancer - Pipeline by La Jolla Pharmaceutical Company, H1 2017
Ovarian Cancer - Pipeline by Laboratoire HRA Pharma, H1 2017
Ovarian Cancer - Pipeline by Lantern Pharma Inc, H1 2017
Ovarian Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by LegoChem Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by Lidds AB, H1 2017
Ovarian Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
Ovarian Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Ovarian Cancer - Pipeline by Loxo Oncology Inc, H1 2017
Ovarian Cancer - Pipeline by Lymphocyte Activation Technologies SA, H1 2017
Ovarian Cancer - Pipeline by Mabion SA, H1 2017
Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
Ovarian Cancer - Pipeline by MacroGenics Inc, H1 2017
Ovarian Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by MaxiVAX SA, H1 2017
Ovarian Cancer - Pipeline by Mebiopharm Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Medestea Research & Production SpA, H1 2017
Ovarian Cancer - Pipeline by MediaPharma Srl, H1 2017
Ovarian Cancer - Pipeline by MedImmune LLC, H1 2017
Ovarian Cancer - Pipeline by Medivir AB, H1 2017
Ovarian Cancer - Pipeline by Merck & Co Inc, H1 2017
Ovarian Cancer - Pipeline by Merck KGaA, H1 2017
Ovarian Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Mersana Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Merus NV, H1 2017
Ovarian Cancer - Pipeline by Microlin Bio Inc, H1 2017
Ovarian Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Minerva Biotechnologies Corp, H1 2017
Ovarian Cancer - Pipeline by Moleculin Biotech Inc, H1 2017
Ovarian Cancer - Pipeline by MolMed SpA, H1 2017
Ovarian Cancer - Pipeline by Monopar Therapeutics LLC, H1 2017
Ovarian Cancer - Pipeline by Morphotek Inc, H1 2017
Ovarian Cancer - Pipeline by Mycenax Biotech Inc, H1 2017
Ovarian Cancer - Pipeline by NantKwest Inc, H1 2017
Ovarian Cancer - Pipeline by Natco Pharma Ltd, H1 2017
Ovarian Cancer - Pipeline by NBE-Therapeutics AG, H1 2017
Ovarian Cancer - Pipeline by Nektar Therapeutics, H1 2017
Ovarian Cancer - Pipeline by Neovacs SA, H1 2017
Ovarian Cancer - Pipeline by Nerviano Medical Sciences Srl, H1 2017
Ovarian Cancer - Pipeline by Neurimmune Holding AG, H1 2017
Ovarian Cancer - Pipeline by NewLink Genetics Corp, H1 2017
Ovarian Cancer - Pipeline by Northwest Biotherapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Novartis AG, H1 2017
Ovarian Cancer - Pipeline by NovaTarg Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Noviga Research AB, H1 2017
Ovarian Cancer - Pipeline by Novogen Ltd, H1 2017
Ovarian Cancer - Pipeline by Noxopharm Ltd, H1 2017
Ovarian Cancer - Pipeline by NuCana BioMed Ltd, H1 2017
Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2017
Ovarian Cancer - Pipeline by OBI Pharma Inc, H1 2017
Ovarian Cancer - Pipeline by Omeros Corp, H1 2017
Ovarian Cancer - Pipeline by Omnitura Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by OncBioMune Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Oncobiologics Inc, H1 2017
Ovarian Cancer - Pipeline by Oncodesign SA, H1 2017
Ovarian Cancer - Pipeline by Oncolix Inc, H1 2017
Ovarian Cancer - Pipeline by Oncolytics Biotech Inc, H1 2017
Ovarian Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by OncoTartis Inc, H1 2017
Ovarian Cancer - Pipeline by OncoTherapy Science Inc, H1 2017
Ovarian Cancer - Pipeline by Oncternal Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Opsona Therapeutics Ltd, H1 2017
Ovarian Cancer - Pipeline by Optimum Therapeutics LLC, H1 2017
Ovarian Cancer - Pipeline by ORCA Therapeutics BV, H1 2017
Ovarian Cancer - Pipeline by OSE Immunotherapeutics, H1 2017
Ovarian Cancer - Pipeline by Oxford BioMedica Plc, H1 2017
Ovarian Cancer - Pipeline by OXIS International Inc, H1 2017
Ovarian Cancer - Pipeline by Pangaea Biotech SL, H1 2017
Ovarian Cancer - Pipeline by Patrys Ltd, H1 2017
Ovarian Cancer - Pipeline by PDS Biotechnology Corp, H1 2017
Ovarian Cancer - Pipeline by PEP-Therapy SAS, H1 2017
Ovarian Cancer - Pipeline by Pfizer Inc, H1 2017
Ovarian Cancer - Pipeline by Pharma Mar SA, H1 2017
Ovarian Cancer - Pipeline by PharmAust Ltd, H1 2017
Ovarian Cancer - Pipeline by Pharmicell Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Plexxikon Inc, H1 2017
Ovarian Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Precision Biologics Inc, H1 2017
Ovarian Cancer - Pipeline by Prima BioMed Ltd, H1 2017
Ovarian Cancer - Pipeline by Probility Media Corp, H1 2017
Ovarian Cancer - Pipeline by Propanac Biopharma Inc, H1 2017
Ovarian Cancer - Pipeline by PsiOxus Therapeutics Ltd, H1 2017
Ovarian Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
Ovarian Cancer - Pipeline by Quintessence Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by Radius Health Inc, H1 2017
Ovarian Cancer - Pipeline by Recepta Biopharma SA, H1 2017
Ovarian Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Rgenix Inc, H1 2017
Ovarian Cancer - Pipeline by Richter Gedeon Nyrt, H1 2017
Ovarian Cancer - Pipeline by Rosetta Genomics Ltd, H1 2017
Ovarian Cancer - Pipeline by Rubicon Biotechnology Inc, H1 2017
Ovarian Cancer - Pipeline by RXi Pharmaceuticals Corp, H1 2017
Ovarian Cancer - Pipeline by Sanofi, H1 2017
Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H1 2017
Ovarian Cancer - Pipeline by SATT North SAS, H1 2017
Ovarian Cancer - Pipeline by Selecta Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by Senhwa Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by Sequoia Sciences Inc, H1 2017
Ovarian Cancer - Pipeline by Siamab Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Sierra Oncology Inc, H1 2017
Ovarian Cancer - Pipeline by Sigma-Tau SpA, H1 2017
Ovarian Cancer - Pipeline by Sillajen Biotherapeutics, H1 2017
Ovarian Cancer - Pipeline by Soricimed Biopharma Inc, H1 2017
Ovarian Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
Ovarian Cancer - Pipeline by Sotio AS, H1 2017
Ovarian Cancer - Pipeline by Starpharma Holdings Ltd, H1 2017
Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Ovarian Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Ovarian Cancer - Pipeline by Supratek Pharma Inc, H1 2017
Ovarian Cancer - Pipeline by Susavion Biosciences Inc, H1 2017
Ovarian Cancer - Pipeline by Symic Biomedical Inc, H1 2017
Ovarian Cancer - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Syros Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Tactiva Therapeutics LLC, H1 2017
Ovarian Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Ovarian Cancer - Pipeline by Takis Srl, H1 2017
Ovarian Cancer - Pipeline by TapImmune Inc, H1 2017
Ovarian Cancer - Pipeline by Targovax ASA, H1 2017
Ovarian Cancer - Pipeline by Tesaro Inc, H1 2017
Ovarian Cancer - Pipeline by The Female Health Company, H1 2017
Ovarian Cancer - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Transgene SA, H1 2017
Ovarian Cancer - Pipeline by TVAX Biomedical Inc, H1 2017
Ovarian Cancer - Pipeline by Tyrogenex Inc, H1 2017
Ovarian Cancer - Pipeline by ValiRx Plc, H1 2017
Ovarian Cancer - Pipeline by Vascular Biogenics Ltd, H1 2017
Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals Inc, H1 2017
Ovarian Cancer - Pipeline by Verastem Inc, H1 2017
Ovarian Cancer - Pipeline by VG Life Sciences Inc, H1 2017
Ovarian Cancer - Pipeline by ViiV Healthcare Ltd, H1 2017
Ovarian Cancer - Pipeline by ViraTherapeutics GmbH, H1 2017
Ovarian Cancer - Pipeline by Zymeworks Inc, H1 2017
Ovarian Cancer - Dormant Projects, H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..6), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..7), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..8), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..9), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..10), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..11), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..12), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..13), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..14), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..15), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..16), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..17), H1 2017
Ovarian Cancer - Dormant Projects, H1 2017 (Contd..18), H1 2017
Ovarian Cancer - Discontinued Products, H1 2017
Ovarian Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017
Ovarian Cancer - Discontinued Products, H1 2017 (Contd..2), H1 2017
Ovarian Cancer - Discontinued Products, H1 2017 (Contd..3), H1 2017 List of Figures
Number of Products under Development for Ovarian Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $2500
USD $5000
USD $7500
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.